<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210402</url>
  </required_header>
  <id_info>
    <org_study_id>REVAMP</org_study_id>
    <nct_id>NCT03210402</nct_id>
  </id_info>
  <brief_title>REmodeling the Left Ventricle With Atrial Modulated Pacing</brief_title>
  <acronym>REVAMP</acronym>
  <official_title>REmodeling the Left Ventricle With Atrial Modulated Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New therapy tested in heart failure with preserved ejection fraction (HFpEF) patients with&#xD;
      approved indications for pacing to determine if elevated pacing therapy is tolerated and&#xD;
      whether there is a signal for efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">March 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant's Ability to Tolerate Therapy</measure>
    <time_frame>Baseline through 12 week follow-up</time_frame>
    <description>Participant's Ability to Tolerate Night Heart Pacing. The outcome of interest is the proportion of subjects who remain in the study. Study exit reasons will include intolerable symptoms, increase in NT-proBNP levels, decrease in LVEF or increase in troponin. The proportion of subjects remaining in study will be calculated along with the lower bound of the one-sided 95% confidence interval.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Elevated night pacing on</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elevated night pacing off</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elevated night pacing on</intervention_name>
    <description>Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times</description>
    <arm_group_label>Elevated night pacing on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elevated night pacing off</intervention_name>
    <description>Device will be programmed to normal lower rates</description>
    <arm_group_label>Elevated night pacing off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has had a market released dual chamber Medtronic Pacemaker with a Sleep&#xD;
             function for at least 3 months&#xD;
&#xD;
          -  Subject is stable on current medications&#xD;
&#xD;
          -  Subject has dyspnea with exertion or diagnosed as NYHA Class II or III Heart Failure&#xD;
&#xD;
          -  Subject has had a prior Echo in past 6 months with: EF ≥ 50% and Diastolic volume &lt;80&#xD;
             ml/m²&#xD;
&#xD;
          -  Subject has evidence of hypertrophy (indexed to body surface area: men 115 g/m², women&#xD;
             95 g/m² or indexed to height: men 49.2 g/m2.7, women 46.7 g/m2.7) or Relative Wall&#xD;
             thickness &gt;0.42, or Wall Thickness&gt;1.2cm (posterior wall)&#xD;
&#xD;
          -  Subject is willing to sign and date the study Informed Consent Form (IC Form) -&#xD;
             Subject is 18 years of age or older, or of legal age to give informed consent per&#xD;
             local law&#xD;
&#xD;
          -  Subject is expected to remain available for follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has permanent AF or AF noted on baseline interrogation rhythm strip&#xD;
&#xD;
          -  Subject has uncontrolled BP; (systolic pressure needs to be &gt;100mmHg and &lt;160mmHg on&#xD;
             medications)&#xD;
&#xD;
          -  Subject has severe stenosis of the aortic or mitral valve, defined as valve area ≤1.0&#xD;
             cm² or severe regurgitation of the aortic or mitral valve&#xD;
&#xD;
          -  Subject has symptomatic Chronic Obstructive Pulmonary Disease (COPD) requiring oxygen&#xD;
&#xD;
          -  Subject's Pacemaker has less than 6 months of Pacemaker battery life&#xD;
&#xD;
          -  Subject had an aortic valve replacement (surgical or TAVR) procedure less than 9&#xD;
             months prior to enrollment&#xD;
&#xD;
          -  Subject's programmed upper rate limit is less than 100 bpm because of concerns of&#xD;
             elevated pacing&#xD;
&#xD;
          -  Subject is unable or unwilling to perform the 6 Minute Walk Test at all scheduled&#xD;
             study visits&#xD;
&#xD;
          -  Subject is currently enrolled or planning to enroll in a potentially confounding trial&#xD;
             during the course of the study (co-enrollment in concurrent studies is only allowed&#xD;
             when documented pre-approval is obtained from the Medtronic study manager)&#xD;
&#xD;
          -  Subject is pregnant&#xD;
&#xD;
          -  Subject meets any exclusion criteria required by local law&#xD;
&#xD;
          -  Subject's life expectancy is less than 12 weeks&#xD;
&#xD;
          -  Subject with medical condition that precludes the patient from participation in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Subject has known coronary disease with Class II angina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Steinhaus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic CRHF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona - Sarver Heart Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Medical Center</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204-6019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2969</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043-4322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-8905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

